


## Claims

1. Combination that consists of at least one gestagen and a  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin or derivatives of these cyclodextrins, which are obtained by etherification or esterification of free alcoholic functions of the cyclodextrins, whereby the gestagen is a 14,17-C<sub>2</sub>-bridged steroid.

2. Combination according to claim 1, whereby the gestagens belong to the group of formula I:



in which

R<sup>3</sup> stands for an oxygen atom, the hydroxyimino group, or two hydrogen atoms,

R<sup>6</sup> stands for a hydrogen, fluorine, chlorine or bromine atom or for an α- or β-position C<sub>1</sub>-C<sub>4</sub> alkyl radical, whereby then R<sup>6'</sup> and R<sup>7</sup> represent hydrogen atoms, or else

R<sup>6'</sup> stands for a hydrogen, fluorine, chlorine or bromine atom or for a C<sub>1</sub>-C<sub>4</sub> alkyl radical, whereby then R<sup>6'</sup> and R<sup>7</sup> represent a common additional bond,

R<sup>7</sup> stands for an α- or β-position C<sub>1</sub>-C<sub>4</sub> alkyl radical, whereby then R<sup>6</sup> and R<sup>6'</sup> represent hydrogen atoms, or else

R<sup>6</sup> and R<sup>7</sup> together stand for an α- or β-position methylene group, and R<sup>6'</sup> stands for a hydrogen atom, or

R<sup>6</sup> and R<sup>6'</sup> together stand for an ethylene group or a methylene group, and R<sup>7</sup> stands for a hydrogen atom,

R<sup>9</sup> and R<sup>10</sup> in each case stand for a hydrogen atom or a common bond,

R<sup>11</sup> and R<sup>12</sup> in each case stand for a hydrogen atom or a common bond,


R<sup>13</sup> stands for a methyl or ethyl group,

R<sup>15</sup> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>3</sub> alkyl radical,

R<sup>16</sup> and R<sup>16'</sup>, independently of one another, stand for a hydrogen atom, a C<sub>1</sub>-C<sub>3</sub> alkyl radical or a C<sub>2</sub>-C<sub>4</sub> alkenyl radical or together for a C<sub>1</sub>-C<sub>3</sub> alkylidene group,

R<sup>15</sup> and R<sup>16</sup> stand for a common bond, and R<sup>16'</sup> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>3</sub> alkyl radical, or

R<sup>15</sup> and R<sup>16</sup> together stand for a ring of partial formula



in which n = 1 and 2, and X means a methylene group or an oxygen atom, and R<sup>16'</sup> stands for a hydrogen atom,

R<sup>171</sup> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>3</sub> alkyl radical,

R<sup>172</sup> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>3</sub> alkyl radical, or a C<sub>2</sub>-C<sub>4</sub> alkenyl radical,

R<sup>171'</sup> and R<sup>172'</sup> in each case stand for a hydrogen atom or for a common bond,

R<sup>21</sup> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>3</sub> alkyl radical,

R<sup>21'</sup> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>3</sub> alkyl radical, or a hydroxy group.

3. Combination according to claim 2, whereby the gestagen is a (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione.

*Seb*  
4. Combination according to one of the preceding claims,  
whereby the cyclodextrin is a  $\beta$ -cyclodextrin.

*A1*  
5. Combination according to one of the preceding claims,  
whereby the cyclodextrin and the gestagen  
are present with  $\beta$ -cyclodextrin in a complex of 1:n  
(gestagen : cyclodextrin, n ≥ 1), and

Sub  
A

are present with  $\gamma$ -cyclodextrin in a complex of 1:n (n  $\geq$  1) (gestagen : cyclodextrin).

6. Combination according to one of the preceding claims as a pharmaceutical agent.

7. Combination according to claim 6 as a stable, oral formulation.

8. Combination according to claim 6 or 7 for the production of a pharmaceutical agent for treating menopausal symptoms.

9. Combination according to one of the preceding claims 1 to 5 for birth control.

10. Pharmaceutical agent or pharmaceutical preparation that contains a combination according to one of the preceding claims with pharmaceutically compatible adjuvants and vehicles.

11. Pharmaceutical agent or pharmaceutical preparation that contains a combination according to one of the preceding claims for peroral, oral, parenteral, transdermal, pulmonary, nasal, rectal, vaginal or intrauterine use.

12. Use of a combination according to one of the preceding claims 1 to 9 for the production of a medication for treating premenstrual symptoms, such as headaches, depression, water retention and mastodynia.

13. Process for birth control with administration of a combination according to one of claims 1 to 9.

14. Process for stabilization of a gestagen according to Formula I according to claim 2 with use of a  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin or derivatives of these cyclodextrins, which are

Sub  
B  
6  
2

obtained by etherification or esterification of free alcoholic functions of cyclodextrins.

*Sub*  
15. Process for complexing a gestagen according to one of claims 1 and 2 and a  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin while being triturated as a dry mixture or by precipitation reaction, preferably co-precipitation.

*a3*  
16. Process for direct pelletizing of a gestagen complex according to one of claims 1 and 2 with a  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin with the addition of pharmaceutically compatible adjuvants.

CONFIDENTIAL